Skip to main content
Clinical Trials/JPRN-UMIN000032729
JPRN-UMIN000032729
Completed
未知

A prospective observational study of patients with advanced cancer for the evaluation of checkpoint inhibitor-associated cardiovascular immune-related adverse events - AWARENESS-irAE registry

Frontline Immunotherapy Team, Sendai Kousei Hospital0 sites129 target enrollmentMay 26, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Advanced non-small-cell lung cancer and advanced gastric cancer which are indications for anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed death-1, and anti-programmed death-ligand 1 antibodies.
Sponsor
Frontline Immunotherapy Team, Sendai Kousei Hospital
Enrollment
129
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 26, 2018
End Date
May 16, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Frontline Immunotherapy Team, Sendai Kousei Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients who undergo hemodialysis or have anaphylactic reactions to immune checkpoint inhibitors

Outcomes

Primary Outcomes

Not specified

Similar Trials